RT Journal Article
SR Electronic
T1 Tiotropium + olodaterol provides significant lung-function benefits compared to fluticasone + salmeterol regardless of prior bronchodilator use
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA978
DO 10.1183/13993003.congress-2016.PA978
VO 48
IS suppl 60
A1 Eric Derom
A1 Kai-Michael Beeh
A1 José Echave-Sustaeta
A1 Lars Grönke
A1 Dongmei Zhai
A1 Leif Bjermer
YR 2016
UL http://erj.ersjournals.com/content/48/suppl_60/PA978.abstract
AB Introduction: The ENERGITO® study demonstrated superior lung function with long-acting muscarinic antagonist (LAMA) tiotropium + long-acting β2-agonist (LABA) olodaterol (T+O) compared to inhaled corticosteroid (ICS) fluticasone + LABA salmeterol (F+S) in patients with COPD.Aim: To investigate if lung-function benefits of T+O compared to F+S were affected by prior ICS, LAMA or LABA treatment in ENERGITO®.Methods: In ENERGITO® (1237.11, NCT01969721; Phase IIIb, randomised, double-blind, double-dummy, four-period crossover), patients with moderate to severe COPD received once-daily T+O 2.5/5 or 5/5 µg and twice-daily F+S 250/50 or 500/50 µg for 6 weeks. A post hoc analysis evaluated FEV1 AUC0–12 and AUC0–24 responses in patients with or without LAMA, LABA or ICS therapy at screening. We describe results comparing T+O 5/5 µg to both doses of F+S.Results: 229 patients were enrolled and treated: 123 received prior LAMA, 141 LABA, 109 ICS. T+O significantly improved FEV1 AUC0–12 and AUC0–24 responses in patients with or without prior LAMA, LABA or ICS therapy compared to F+S (Table).Conclusions: In ENERGITO®, patients with moderate or severe COPD showed improved lung function with T+O compared to F+S regardless of prior treatment. T+O is a better choice than LABA/ICS to optimise lung function when initiating maintenance treatment.Funding: Boehringer Ingelheim.